Alivus Life Sciences (NSE:ALIVUS) EV-to-OCF: (As of Sep. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ALIVUS Alivus Life Sciences Ltd NSE:ALIVUS
76 GF Score
Price ₹1,386.80
GF Value ₹1,052.53
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Alivus Life Sciences EV-to-OCF?

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Alivus Life Sciences's Enterprise Value is ₹162,801 Mil. Alivus Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil. Therefore, Alivus Life Sciences's EV-to-OCF for today is .

The historical rank and industry rank for Alivus Life Sciences's EV-to-OCF or its related term are showing as below:

NSE:ALIVUS' s EV-to-OCF Range Over the Past 10 Years
Min: 28.79   Med: 0   Max: 28.79
Current: 28.79

During the past 8 years, the highest EV-to-OCF of Alivus Life Sciences was 28.79. The lowest was 28.79. And the median was .

NSE:ALIVUS's EV-to-OCF is ranked worse than
78.93% of 1006 companies
in the Drug Manufacturers industry
Industry Median: 10.305 vs NSE:ALIVUS: 28.79

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-09-12), Alivus Life Sciences's stock price is ₹1386.80. Alivus Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹49.030. Therefore, Alivus Life Sciences's PE Ratio (TTM) for today is 28.28.


Alivus Life Sciences  (NSE:ALIVUS) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Alivus Life Sciences's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1386.80/49.030
=28.28

Alivus Life Sciences's share price for today is ₹1386.80.
Alivus Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹49.030.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Alivus Life Sciences EV-to-OCF Related Terms


Alivus Life Sciences EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Alivus Life Sciences's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alivus Life Sciences EV-to-OCF Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EV-to-OCF
Get a 7-Day Free Trial 8.55 14.82 22.29 32.53 19.86

Alivus Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EV-to-OCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 19.86 0.00

NSE:ALIVUS vs ZTS: EV-to-OCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alivus Life Sciences EV-to-OCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where Alivus Life Sciences's EV-to-OCF falls into.


NSE:ALIVUS
76GF Score
Alivus Life Sciences Ltd NSE:ALIVUS
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alivus Life Sciences EV-to-OCF Calculation

Alivus Life Sciences's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=162800.971/0
=

Alivus Life Sciences's current Enterprise Value is ₹162,801 Mil.
Alivus Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?

Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued. The current stock price of ₹1,386.80 is trading 31.8% above its estimated GF Value™ of ₹1,052.53. GuruFocus considers Alivus Life Sciences to be Significantly Overvalued.

Key valuation signals for NSE:ALIVUS:

  • EV-to-OCF:
  • GF Value™: ₹1,052.53 vs. price of ₹1,386.80 (31.8% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alivus Life Sciences Business Description

Other Exchanges 543322:India
Address 470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
76GF Score

Get the complete analysis for NSE:ALIVUS

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,386.80
Price
₹1,052.53
GF Value